709P Real-world systemic treatment patterns of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC)

Atezolizumab plus bevacizumab (atezo+bev) is standard of care first-line treatment in eligible patients with advanced HCC, but clear guidance on follow-up treatment is lacking. In IMbrave150, 36% of patients received systemic treatment after atezo+bev. Real-world evidence is needed to describe treatment patterns in clinical practice. This study describes the real-world use of atezo+bev and subsequent systemic treatments in patients with HCC in the United States (US).